UNITED STATES For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-36353 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Perrigo Company plc (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Irelan ...

Perrigo Company (NYSE:PRGO) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsBradley Joseph - VP and Head of Global Investor RelationsDaniel Biolsi - Managing DirectorEduardo Bezerra - CFOKeith Devas - VPPatrick Lockwood-Taylor - President and CEOConference Call ParticipantsSusan Anderson - Managing Direct and Senior AnalystNone - AnalystOperatorGood morning, ladies and gentlemen, welcome to Perrigo Q4 2025 financial results conference call. At this time, all lines are in a listen-onl ...

Perrigo Company (NYSE:PRGO) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsBradley Joseph - VP and Head of Global Investor RelationsDaniel Biolsi - Managing DirectorEduardo Bezerra - CFOKeith Devas - VPPatrick Lockwood-Taylor - President and CEOConference Call ParticipantsSusan Anderson - Managing Direct and Senior AnalystNone - AnalystOperatorGood morning, ladies and gentlemen, welcome to Perrigo Q4 2025 financial results conference call. At this time, all lines are in a listen-onl ...

Perrigo Company (NYSE:PRGO) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker5Good morning, ladies and gentlemen, welcome to Perrigo Q4 2025 financial results conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, February 26th, 2026. I would now like to turn the co ...

Q4 & FY2025 Earnings Presentation February 26, 2026 Bradley Joseph VP Global Investor Relations 3 Agenda Brad Joseph • Introduction Patrick Lockwood-Taylor Eduardo Bezerra Forward-Looking Statements Certain statements in this presentation are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and u ...

EXHIBIT 99.1 Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook Range Advanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share in 2025, Despite Soft Category Consumption 1,2 Launching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized Savings of $80 million to $100 million Transitioning to New Reporting Segments Beginning Q1 2026, Aligned to Commercial Ope ...

Core Insights - The company delivered FY2025 adjusted EPS at the midpoint of the updated outlook range, indicating stable performance despite market challenges [1] - The '3-S Plan' is advancing with Perrigo Store Brand OTC and key brands gaining market share in 2025, despite soft category consumption [1] - A new operational enhancement program is being launched, expected to deliver pre-tax annualized savings of $80 million to $100 million [1] - The company will transition to new reporting segments beginning Q1 2026, aligning with its commercial operating model [1] - FY2026 'All In' outlook has been issued, along with the introduction of FY2026 'CORE' outlook, which excludes infant formula and previously announced divestitures [1] Financial Performance - For Q4 2025, net sales were reported at $1.11 billion, reflecting a year-over-year decline of 2.5% [1] - Favorable foreign exchange contributed positively by 2.3%, but this was more than offset by organic net sales decline of 4.5% and the impact of divestitures and exited products, which accounted for a 0.4% decrease [1]

Wall Street analysts expect Perrigo (PRGO) to post quarterly earnings of $0.80 per share in its upcoming report, which indicates a year-over-year decline of 14%. Revenues are expected to be $1.1 billion, down 3.2% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces its earnings, it is essential ...

Perrigo (PRGO) closed the last trading session at $14.55, gaining 1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.67 indicates a 28.3% upside potential.The average comprises three short-term price targets ranging from a low of $18.00 to a high of $20.00, with a standard deviation of $1.15. While the lowest estimate indicates an increase of 23.7% from the current price level, ...

Core Viewpoint - Perrigo Company plc is set to release its fourth quarter and fiscal year 2025 financial results on February 26, 2026, with a conference call scheduled for 8:30 A.M. (EST) [1] Company Overview - Perrigo is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [1] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers [1] - Perrigo's business model leverages complementary businesses, where cash-generative store brand private label offerings support investments in leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [1]